KAM
SVA

Kassirer Asset Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Kassirer Asset Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,000
Closed -$59K – 128
2016
Q2 		$59K Hold
10,000
– – 0.03% 93
2016
Q1 		$64K Buy
+10,000
New +$60K 0.06% 81

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Kassirer Asset Management's SVA Position: Q3 2016 in Review

Kassirer Asset Management sold out of Sinovac Biotech, Ltd (SVA) in Q3 2016, closing a stake of 10,000 shares — an estimated $59K sold.

Kassirer Asset Management first reported a position in SVA in Q1 2016 and held it in 2 quarters. The position peaked at $64K in Q1 2016. 36 funds tracked by Wall St. Rank hold SVA as of Q3 2016.

  • Kassirer Asset Management reported no remaining Sinovac Biotech, Ltd position as of Q3 2016 after selling out during the quarter.
  • Kassirer Asset Management sold 10,000 Sinovac Biotech, Ltd shares in Q3 2016, an estimated $59K.
  • Kassirer Asset Management first reported a position in Sinovac Biotech, Ltd in Q1 2016 and held it in 2 quarters.
  • Kassirer Asset Management's Sinovac Biotech, Ltd position peaked at $64K in Q1 2016.
  • 36 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2016.

Based on Kassirer Asset Management's 13F filing for Q3 2016, filed 20 Oct 2016.